Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6826741 | 0.92 | NPY5R (0.65) | NPY5RKMT2AKDM4EHSD17B10GAA | |
| SCHEMBL6826755 | 0.91 | NPY5R (0.64) | NPY5RKMT2AKDM4EHSD17B10GAA | |
| SCHEMBL6826947 | 0.90 | NPY5R (0.62) | NPY5RKMT2AKDM4EHSD17B10GAA | |
| SCHEMBL6823912 | 0.89 | NPY5R (0.73) | NPY5RKDM4EGAACREBBPALDH1A1 | |
| SCHEMBL6828937 | 0.85 | NPY5R (0.67) | NPY5RKMT2AKDM4EHSD17B10GAA | |
| SCHEMBL6827398 | 0.83 | NPY5R (0.55) | NPY5RKMT2AKDM4EHSD17B10GAA | |
| SCHEMBL6829275 | 0.80 | NPY5R (0.69) | NPY5RKMT2AMAPTHTTRAB9A | |
| SCHEMBL29434775 | 0.79 | NPY5R (1.00) | NPY5RKMT2AKDM4EHSD17B10MAPT | |
| SCHEMBL6826732 | 0.79 | NPY5R (1.00) | NPY5RKMT2AKDM4EHSD17B10MAPT | |
| SCHEMBL6827663 | 0.79 | NPY5R (0.67) | NPY5RKMT2AKDM4EHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | NPY5R 1/4885KMT2A 3618/4885KDM4E 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.